Halozyme Therapeutics Inc. Stock
Halozyme Therapeutics Inc. gained 1.810% today.
Halozyme Therapeutics Inc. is currently one of the favorites of our community with 12 Buy predictions and no Sell predictions.
As a result the target price of 54 € shows a positive potential of 47.82% compared to the current price of 36.53 € for Halozyme Therapeutics Inc..
Pros and Cons of Halozyme Therapeutics Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
B****
?
G***** c******* t* c**********
Cons
?
S********** s********
?
C******** o* t** e**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Halozyme Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Halozyme Therapeutics Inc. | 1.810% | 0.717% | -2.639% | 25.317% | 7.917% | -13.681% | - |
| Novocure Ltd | 1.610% | 5.242% | -17.421% | -80.032% | -16.322% | -92.944% | - |
| Sage Therapeutics Inc. | 2.860% | 5.711% | -23.937% | -69.363% | -33.825% | -79.582% | - |
| Iovance Biotherapeutics Inc. | 3.910% | 5.642% | -17.813% | 119.691% | 43.891% | -56.555% | - |
Comments
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $50.00 price target on the stock.
Show more
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its price target raised by analysts at HC Wainwright from $48.00 to $50.00. They now have a "buy" rating on the stock.
Show more
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $50.00 price target on the stock.
Show more
Ratings data for HALO provided by MarketBeat